# AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

> **NCT06793371** · PHASE2 · RECRUITING · sponsor: **Cytokinetics** · enrollment: 60 (estimated)

## Conditions studied

- Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)

## Interventions

- **DRUG:** CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)
- **DRUG:** Placebo to match CK-4021586

## Key facts

- **NCT ID:** NCT06793371
- **Lead sponsor:** Cytokinetics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-06
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06793371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06793371, "AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06793371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*